Literature DB >> 10904846

The outcome of coxsackievirus B3-(CVB3-) induced myocarditis is influenced by the cellular immune status.

C Leipner1, K Grün, M Borchers, A Stelzner.   

Abstract

Mice develop a marked age-related susceptibility to myocardial coxsackievirus B3 (CVB3) infections. The lesions observed in mice resemble closely those seen in the human disease. Experimental murine models of CVB3-induced myocarditis have shown that both, host and viral genetic factors, can influence susceptibility to the infection as well as the persistence and progression of the disease. Recently, we have shown that CD4 T cell-deficient MHC Class II knockout mice develop a strong fibrosis with virus persistence in the heart tissue and without production of neutralizing antibodies. To examine the role of CD4+ T cells and especially the role of the T helper 1 cell response for the outcome and pathogenesis of CVB3-induced myocarditis in more detail, 2 different mouse strains with identical genetic background (H-2b) were infected with CVB3-Mü/J (Nancy strain). Immunocompetent C57BL/6 mice and mice with targeted disruption of interleukin (IL-)4 gene (IL-4-/- mice) developed a severe acute myocarditis on day 7 post infection (p.i.). The CVB3-induced inflammation was cured until the 21st day p.i. in hearts of C57BL/6 mice. IL-4-/- mice with insufficient T helper-2 cell immune response developed a severe myocardial damage between day 7 and 21 p.i. with prolonged virus persistence in the heart tissue. Therefore, we suggest that despite an obvious normal T helper-1 cell cytokine pattern, IL-4-/- mice are more susceptible to long-term heart muscle injuries after infection with CVB3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10904846     DOI: 10.1007/s000590050014

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  8 in total

Review 1.  Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all.

Authors:  Muhammad Abdullah; Jessica M Berthiaume; Monte S Willis
Journal:  Transl Res       Date:  2017-11-07       Impact factor: 7.012

2.  beta2-microglobulin-associated regulation of interferon-gamma and virus-specific immunoglobulin G confer resistance against the development of chronic coxsackievirus myocarditis.

Authors:  Karin Klingel; Jens-Jörg Schnorr; Martina Sauter; Gudrun Szalay; Reinhard Kandolf
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 3.  Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.

Authors:  Chandirasegaran Massilamany; Arunakumar Gangaplara; Jay Reddy
Journal:  Int J Cardiol       Date:  2014-10-18       Impact factor: 4.164

4.  Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

Authors:  A Henke; R Zell; G Ehrlich; A Stelzner
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression.

Authors:  Huifang M Zhang; Ji Yuan; Paul Cheung; David Chau; Brian W Wong; Bruce M McManus; Decheng Yang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

6.  Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice.

Authors:  Carola Leipner; Katja Grün; Ilka Schneider; Brigitte Glück; Holger H Sigusch; Axel Stelzner
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

7.  Effect of interleukin-15 on the course of myocarditis in Coxsackievirus B3-infected BALB/c mice.

Authors:  Boris Bigalke; Peter L Schwimmbeck; Christian S Haas; Stephan Lindemann
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

8.  A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-κB signaling.

Authors:  Jun Gui; Yan Yue; Ruizhen Chen; Wei Xu; Sidong Xiong
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.